On March 02th, our recently work "Rational design of rigid mRNA folding architecture to enhance intracellular processing and protein production" was published on Nature Nanotechnology (2026, doi: org/10.1038/s41565-025-02114-9). Our laboratory has focused on nanomedicine and gene therapy. Here we develop a metal-ion-assisted RNA folding (MARF) strategy which affects the global folding state of RNA molecules and specific metal ions that can increase protein production have been discovered. Specifically, MARF altered the mechanical cues of mRNA-based lipid nanoparticles (LNPs) and the surrounding cell membrane, thus regulating intracellular processing and the physiological fate of delivered mRNA. MARF achieved significantly higher protein expression, due not only to enhanced cytosolic delivery but also the accumulation and sequestration of LNPs in h...

课题组因科研工作与临床转化发展需要，现面向全球公开招聘博士后研究人员若干名。 一、导师及项目简介 陈小元（Shawn Chen）教授是纳米医学、分子影像及生物材料领域的国际顶级专家，欧洲科学院、欧盟科学院、新加坡国家科学院院士。发表SCI论文1200余篇（引用超18万次，H指数220），连续多年入选科睿唯安“全球高被引科学家”；研究成果多次在国际顶级期刊发表。团队核心研究方向为可临床转化的诊疗一体化技术开发，开创性研发了新型分子影像探针、纳米材料，并将其应用于药物研发、基因治疗、免疫治疗等领域。 陈教授团队依托山东省肿瘤医院与多所海外知名大学开展密切合作。因合作需求，面向全球招聘优秀博士后，旨在培养具有国际视野、能够冲击国家级人才计划的优秀青年学者。 二、招聘条件 （一）已获得或即将获得药学、化学、生物医学工程、分子生物学、核医学、肿瘤学、材料科学、生物化学等相关专业博士学位，博士毕业不超过3年，年龄一般在35周岁以下，品学兼优，身体健康； （二）研究方向与课题组一致或有相关交叉，具有独立开展科研工作的...

Recently released in the 2024 Journal Citation Reports™ (JCR) by Clarivate, the Impact Factor of Theranostics has significantly increased to 13.3, marking progressive growth from the previous year's IF of 12.4. This achievement further underscores the journal's prominent position in the fields of translational medicine and precision medicine. According to the JCR 2024, The IF 13.3 of Theranostics not only sets a new historical high for the journal but also firmly places it among the top tier (top 1%) of global medical journals (Medicine category). The journal has consistently demonstrated growth over multiple consecutive years. This accomplishment reflects the high recognition by the global scientific community of the academic quality, innovative value, and international citation impact of the research published in Theranostics. As a flagship journal in t...

On June 16th, our recently work “A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy” was published on Nature Nanotechnology (2025, doi: org/10.1038/s41565-025-01952-x). Our laboratory has focused on biomimetic nanovesicle-based drug delivery and immunotherapy. Here we propose a nanovaccine strategy, called NICER, based on a nanovesicle system integrating CSC-specific antigen display and epigenetic nano-regulator encapsulation with a dendritic-cell-targeting aptamer. Specifically, nanovesicles derived from aldehyde-dehydrogenase-overexpressing tumours could serve as integrated antigens carrying both CSC-specific antigen and tumour-associated antigens. Epigenetic nano-regulator targeting YTH N6-methyladenosine RNA binding protein 1 could restrict dendritic cell lysosomal protease activity to modulate...